Conditions: Non-ischemic Cardiomyopathy Systolic Heart Failure (NYHA II-III)
Keywords: heart failure non-ischemic cardiomyopathy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 10
Healthy volunteers: no

Brief summary:
Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of systemic inflammation.

Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful anti-inflammatory effects.

In this study we plan to determine the effects of Doxycycline in patients with stable heart failure and non-ischemic cardiomyopathy on peak of aerobic exercise capacity (peak V02) and ventilator efficiency measured with a cardiopulmonary test.

Detailed description:
In this study of Safety and Efficacy of Doxycycline in Patients with Non-Ischemic Cardiomyopathy Population, we will enroll 24 patients with a clinical diagnosis of heart failure and non-ischemic cardiomyopathy (recent imaging study documenting LV ejection fraction \<50%, and no history of coronary or ischemic heart disease) in a single-center, randomized, double-blinded, placebo-controlled clinical trial with allocation 1:1:1 to Doxycycline 100 mg twice daily or Doxycycline 20 mg twice daily or Placebo for 2 weeks.

Arms:
arm 1: Doxycycline 100 mg twice daily for 14 days arm 2: Doxycycline 20 mg twice daily for 14 days arm 3: Placebo

Interventions: intervention 1: Doxycycline intervention 2: placebo
Intervention descriptions: intervention 1: Doxycycline 1 tablet every 12 hours for 14 days intervention 2: Placebo 1 tablet every 12 hours for 14 days

Protocol document: